Parathyroid carcinoma is a unique malignant tumor, the primary clinical manifestations of which are hyperfunction of the parathyroid gland, various metabolic disorders secondary to hypercalcemia and corresponding impairment of tissues and organs. A complete laboratory examination, accurate imaging, and reliable histopathologic findings are critical to the diagnosis of parathyroid carcinoma. Parathyroid carcinoma is insensitive to chemotherapy and radiotherapy. Immunotherapy is a technology developed in recent years that provides a novel pathway to treat hypercalcemia that is resistant to traditional therapeutic methods. In this study, an anti-parathyroid hormone (PTH) autoantibody produced by the immunization of artificially synthesized human and bovine PTH peptide was used. We aimed to report the efficacy of this therapy in the treatment of parathyroid carcinoma.
Key words: Parathyroid carcinoma, immunotherapy, anti-parathyroid hormone.
Copyright © 2019 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0